查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1392121

骨髓增生性腫瘤 (MPN) 治療市場：按疾病類型、按藥物類別、按配銷通路、按地區

Myeloproliferative Neoplasms Treatment Market, By Disease Type, By Drug Class, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2023 年，全球骨髓增生性腫瘤 (MPN) 治療市場將達到 94 億美元，預測期內（2023-2030 年）年複合成長率為 3.9%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 94億美元
實績資料 2018-2021 預測期 2023-2030
預測期年複合成長率 3.90% 2030年市場規模預測 122.8億美元
圖 1. 2023 年按疾病類型分類的骨髓增生性腫瘤 (MPN) 治療的全球市場佔有率(%)
骨髓增生性腫瘤治療市場-IMG1

骨髓增生性腫瘤（MPN）是一組罕見的骨髓疾病，會導致血球數量增加。與骨髓增生性腫瘤 (MPN) 相關的症狀包括頻繁頭痛、疲勞、瘀傷或異常出血、視力模糊、耳鳴以及眼部問題（例如比平常更具傳染性）。此外，骨髓增生性腫瘤（MPN）的診斷需要進行血液檢查，該檢查可以顯示血球的數量並可以檢查基因突變。還可以進行其他檢查，例如骨髓檢查和腹部超音波。

市場動態

骨髓增生性腫瘤（MPN）治療產業的主要參與者正在專注於研究和開發，以開發骨髓增生性腫瘤（MPN）的創新治療方法。因此，市場研發活動的增加預計將在預測期內推動全球骨髓增生性腫瘤（MPN）治療市場的成長。例如，2023 年 2 月 23 日，PharmaEssentia 總公司是一家總部位於台灣的全球生物製藥創新公司，利用深厚的專業知識和經過驗證的科學原理，在血液學和腫瘤學領域提供新型生技藥品。PharmaEssentia USA Corporation是PharmaEssentia USA Corporation 的子公司，宣布第一位患者已開始在一項2B 期臨床試驗中給藥，該試驗評估了rodeginterferon alfa-2b-njft 用於治療成人原發性血小板增多症(ET) 的效果。 BESREMi（ropeginterferon alfa-2b-njft）是一種創新的單聚乙二醇化長效干擾素。 BESREMi由於其獨特的聚乙二醇化技術，在體內的活性持續時間較長，可以每兩週給藥一次（如果血液學穩定超過一年則可以每四周給藥一次），可根據患者的個體需要靈活給藥。

本次測試的主要特點

  • 本報告對全球骨髓增生性腫瘤（MPN）治療藥物市場進行了詳細分析，並列出了以2022年為基準年的預測期（2023-2030年）的市場規模和年複合成長率。它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
  • 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 根據公司亮點、產品系列、主要亮點、績效和策略等參數，對全球骨髓增生性腫瘤 (MPN) 治療市場的主要企業進行了分析。
  • 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
  • 全球骨髓增生性腫瘤 (MPN) 治療市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 透過用於分析全球骨髓增生性腫瘤（MPN）治療的各種策略矩陣，將有助於相關人員做出決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 假設
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章 市場動態、法規及趨勢分析

  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
  • 影響分析
  • 監管場景
  • 流行病學
  • 合併、收購和合作
  • 監管場景
  • 主要進展
  • PEST分析

第4章 全球骨髓增生性腫瘤（MPN）治療市場-新型冠狀病毒感染疾病（COVID-19）的影響分析

  • 經濟影響
  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 對需求和供給的影響

第5章 2018-2030年全球骨髓增生性腫瘤（MPN）治療市場（依疾病類型）

  • 原發性血小板增多症（ET）
  • 骨髓纖維化（MF）
  • 真性多血症(PV)

第6章 2018-2030 年全球骨髓增生性腫瘤 (MPN) 治療市場（依藥物類別）

  • 酪胺酸激化酵素抑制劑
  • Janus激化酵素抑制劑
  • 拮抗
  • 其他

第7章 全球骨髓增生性腫瘤 (MPN) 治療市場（依配銷通路），2018-2030 年

  • 醫院藥房
  • 零售藥房
  • 線上藥房

第8章 2018-2030年全球骨髓增生性腫瘤（MPN）治療市場（按地區）

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中東
  • GCC
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章 競爭形勢

  • 公司簡介
    • Novartis AG
    • PharmaEssentia Corporation
    • Bristol Myers Squibb
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Incyte
    • Johnson &Johnson
    • Teva Pharmaceutical Industries Ltd
    • F. Hoffmann-La Roche AG
    • Gamida Cell
    • Sierra Oncology, Inc
    • CTI BioPharma Corp
    • Imago BioSciences
    • AbbVie Inc
    • Constellation Pharmaceuticals

第10章 章

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI930

The Global Myeloproliferative Neoplasms Treatment Market is estimated to be valued at US$ 9.4 Billion in 2023 and is expected to exhibit a CAGR of 3.9% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 9.4 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 3.90% 2030 Value Projection: US$ 12.28 Bn
Figure 1. Global Myeloproliferative Neoplasms Treatment Market Share (%), By Disease Type, 2023
Myeloproliferative Neoplasms Treatment Market - IMG1

Myeloproliferative neoplasms are a group of rare disorders of the bone marrow that cause an increase in the number of blood cells. The symptoms associated with Myeloproliferative Neoplasms include frequent headaches, tiredness, bruising or unusual bleeding, problem with eyes - such as blurred vision, ringing in the ears, getting more infectious than usual. Moreover, the diagnosis involves blood test to diagnose myeloproliferative neoplasms, the blood tests show the number of blood cells, and can look for genetic mutations. Also, there are other test which done like a bone marrow test, an ultrasound of abdomen.

Different myeloproliferative disorders affect different blood cells that form in the bone marrow. The bone marrow is the soft inner part of bones that makes the blood cells. There are number of different types of myeloproliferative disorders exist, which are;

  • Chronic myeloid leukaemia (CML)
  • Polycythaemia vera
  • Essential thrombocythaemia
  • Primary myelofibrosis

Market Dynamics

The key players in the myeloproliferative neoplasm treatment industry are focusing on research and development to develop innovative treatment for myeloproliferative neoplasm. Thus, an increase in research and developement activities in the market is expected to drive the global myeloproliferative neoplasms treatement market growth over the forecast period. For instance, on February 23, 2023, PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that the first patient is now being dosed in a phase 2b clinical study evaluating ropeginterferon alfa-2b-njft for the treatment of adults with essential thrombocythemia (ET). BESREMi (ropeginterferon alfa-2b-njft) is innovative monopegylated, long-acting interferon. With its unique pegylation technology, BESREMi has a long duration of activity in the body and is aimed to be administered once every two weeks (or every four weeks with hematological stability for at least one year), allowing flexible dosing that helps meet the individual needs of patients.

Key features of the study:

  • This report provides an in-depth analysis of the global myeloproliferative neoplasms treatment market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global myeloproliferative neoplasms treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Novartis AG, PharmaEssentia Corporation, Bristol Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc, CTI BioPharma Corp, Imago BioSciences, AbbVie Inc, and Constellation Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global myeloproliferative neoplasms treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myeloproliferative neoplasms treatment

Detailed Segmentation:

  • By Disease Type:
    • Essential Thrombocythemia (ET)
    • Myelofibrosis (MF)
    • Polycythemia Vera (PV)
  • By Drug Class:
    • Tyrosine Kinase Inhibitors
    • Janus kinase inhibitors (JAKi)
    • Antimetabolites
    • Others (alkylating agents, etc.)
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • Novartis AG
    • PharmaEssentia Corporation
    • Bristol Myers Squibb
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Incyte
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd,
    • F. Hoffmann-La Roche AG
    • Gamida Cell
    • Sierra Oncology, Inc
    • CTI BioPharma Corp
    • Imago BioSciences
    • AbbVie Inc
    • Constellation Pharmaceuticals

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Disease Type
    • Market Snippet, By Drug Class
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Regulatory Scenario
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Myeloproliferative Neoplasms Treatment Market - COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Myeloproliferative Neoplasms Treatment Market, By Disease Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Essential Thrombocythemia (ET)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Myelofibrosis (MF)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Polycythemia Vera (PV)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

6. Global Myeloproliferative Neoplasms Treatment Market, By Drug Class, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Tyrosine Kinase Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Janus Kinase Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Antimetabolites
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

7. Global Myeloproliferative Neoplasms Treatment Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global Myeloproliferative Neoplasms Treatment Market, By Region, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Region/Country, 2018 -2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • Novartis AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • PharmaEssentia Corporation
    • Bristol Myers Squibb
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Incyte
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd
    • F. Hoffmann-La Roche AG
    • Gamida Cell
    • Sierra Oncology, Inc
    • CTI BioPharma Corp
    • Imago BioSciences
    • AbbVie Inc
    • Constellation Pharmaceuticals

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact